Helicobacter pylori \(\gamma\)-glutamyl transpeptidase: A formidable virulence factor

Samantha Shi Min Ling, Khay Guan Yeoh, Bow Ho

Abstract

Helicobacter pylori (H. pylori) produce an enzyme known as \(\gamma\)-glutamyl transpeptidase (HpGGT) that is highly conserved and common to all strains. HpGGT has been gaining increasing attention as an important virulence factor of the bacterium, having been demonstrated to be an important colonization factor in several animal models and has also recently been strongly associated with the development of peptic ulcer disease. From the results of various independent researcher groups, it is clear that HpGGT acts through several pathways to damage gastric epithelial cells including induction of apoptosis and cell cycle arrest, production of reactive oxygen species, promotion of inflammation and upregulation of heparin-binding epidermal growth factor-like growth factor which may then lead to carcinogenesis. HpGGT also has immunomodulatory actions on immune cells where it displays an antiproliferative effect on T cells and skew dendritic cells towards a tolerogenic phenotype, possibly contributing to the persistence of the pathogen in the gastric mucosa.

Key words: Helicobacter pylori; Gamma-glutamyl transpeptidase; Pathogenesis; Immunomodulation; Carcinogenesis

Core tip: Helicobacter pylori produce \(\gamma\)-glutamyl transpeptidase (HpGGT), an important virulence factor associated with the development of peptic ulcer disease. HpGGT acts through several pathways to damage gastric epithelial cells including induction of apoptosis and cell cycle arrest, production of reactive oxygen species, promotion of inflammation and upregulation of heparin-binding epidermal growth factor-like growth factor which may then lead to carcinogenesis. HpGGT also has immunomodulatory actions on immune cells where it displays an antiproliferative effect on T cells and skew dendritic cells towards a tolerogenic phenotype, possibly contributing to the persistence of the pathogen in the gastric mucosa.

Ling SSM, Yeoh KG, Ho B. Helicobacter pylori \(\gamma\)-glutamyl transpeptidase: A formidable virulence factor. World J Gastroenterol 2013 December 7; 19(45): 8203-8210 Available from: URL: http://www.wjgnet.com/1007-9327/full/v19/i45/8203.htm DOI: http://dx.doi.org/10.3748/wjg.v19.i45.8203
INTRODUCTION

*Helicobacter pylori* (H. pylori) is a Gram-negative, spiral-shaped bacterium that selectively colonizes the human gastric mucosa. It has been reported to chronically infect at least half of the world’s population\(^{1-3}\) and may persist for life in the absence of appropriate treatment. *H. pylori* is a major etiological factor of a range of gastroduodenal diseases including chronic gastritis\(^8\) and peptic ulcer disease\(^4\), and has been closely associated with the development of mucosa-associated lymphoid tissue lymphoma\(^8\) and even gastric cancer\(^9\).

Since the first isolation of *H. pylori* in 1983\(^1\), numerous virulence factors of the pathogen have been identified including the extensively studied cytotoxin-associated gene A (CagA)\(^8\) and vacuolating cytotoxin (VacA)\(^9\). In western countries, strains harbouring CagA and VacA (with s1/mL alleles) have been strongly associated with peptic ulcer disease and gastric cancer\(^10\). However, their relevance in East Asia remains unclear as such correlations were not apparent\(^12\). From these observations, it can be inferred that CagA and VacA are probably not the only factors contributing to *H. pylori* pathogenesis. There is thus a constant search for other pathogenic factors that could aid in the virulence of the bacterium. One such factor is *H. pylori* γ-glutamyl transpeptidase (HpGGT) which has been gaining increasing attention in recent years and will be the main focus of this review.

PROPERTIES AND FUNCTIONS OF HpGGT

Similar to mammalian GGTs, HpGGT catalyzes reactions in which a γ-glutamyl moiety is transferred from γ-glutamyl compounds, such as glutathione, to amino acids (transpeptidation) or water (hydrolysis)\(^14\). HpGGT is first translated in a single-chain precursor form which is inactive. The proenzyme then undergoes intramolecular autocatalytic cleavage, resulting in a catalytically active heterodimer comprising a large (40 kDa) and small (20 kDa) subunit. Interestingly, the amino acid sequence of HpGGT is considerably different from the GGTs of other bacterial species, sharing only 52.5%, 47.7% and 38% amino acid sequence identities with *Escherichia coli*, *Pseudomonas aeruginosa* and *Bacillus subtilis* GGTs, respectively\(^18\). Among different *H. pylori* strains however, HpGGT is highly conserved with > 97% sequence homology between isolates\(^16\). Notably, HpGGT is also constitutively expressed and is commonly found in all *H. pylori* strains\(^15\), suggesting its importance in the physiology of the bacterium. In further support of this, a subsequent study by Gong and Ho\(^17\) demonstrated the importance of HpGGT in the growth of *H. pylori* where strains with higher GGT activity exhibited more profuse growth compared to those having lower GGT activity. Indeed, it was later found that one of the main physiological functions of HpGGT is to metabolize extracellular glutathione and glutamine (substrates that it is unable to uptake directly) as a source of glutamate which is then taken up by the bacterium and subsequently incorporated into the tricarboxylic acid cycle\(^18\).

HpGGT and colonization

Although not essential for *in vitro* survival, two pioneer studies on HpGGT had earlier demonstrated the enzyme to be an important virulence factor of the gastric pathogen\(^15,19\). Using the Swiss specific pathogen-free murine model, Chevalier et al\(^15\) first described HpGGT to be essential for colonization as *H. pylori* SS1 GGT-deficient mutants could not be recovered from the mice stomachs from 3-60 d post-infection. Interestingly, McGovern et al\(^19\) later showed using two different animal models, namely gnotobiotic piglets and C57BL/6 mice, that although the *H. pylori* HpM5 ggt-isogenic mutants were still able to colonize the animals, the bacterial load was significantly reduced compared to the parental strain. The differences in animal models and *H. pylori* strains used by both groups could have contributed to the variations observed but nevertheless, both studies had consistently shown that the presence of HpGGT provides an advantage to the bacterium in colonization.

Association between HpGGT and peptic ulcer disease

The clinical importance of HpGGT was reported by our group in 2010 where *H. pylori* isolates from patients with peptic ulcer disease (\(n = 54\)) were found to have significantly higher GGT activity (\(P < 0.001\)) compared to those cultured from patients with non-ulcer dyspepsia (\(n = 44\))\(^15\). Furthermore, no correlation was observed between HpGGT and other known virulence genes such as *cagA*, *vacA*, *iceA* and *babA*, suggesting a causal link between HpGGT and gastroduodenal diseases. The exact mechanisms detailing how the presence of HpGGT leads to disease development have not been fully elucidated. However, several pathways involving both gastric epithelial cells as well as immune cells have been put forward by various groups and these will be discussed in this review.

EFFECTS OF HpGGT ON GASTRIC EPITHELIAL CELLS

HpGGT induces apoptosis

*H. pylori*-induced apoptosis of gastric epithelial cells both *in vitro* and *in vivo* had earlier been described by many researchers\(^20-22\), however the bacterial factor(s) responsible were not clearly defined. By analyzing various *H. pylori* membrane fractions capable of inducing apoptotic cell death in AGS cells, HpGGT was later found to be one of the leading factors involved in the induction of apoptosis by *H. pylori*\(^23\). The pathway by which this occurs is mitochondria-mediated as evident from the accompanying activation of caspases 9 and 3, upregulation of pro-apoptotic Bax and downregulation of antiapoptotic Bel-2 and Bel-xL, as well as the release of cytochrome c from the mitochondria into the cytosolic space\(^23\). In addition, it has also been shown by Kim et al\(^23\) that HpGGT inhibits cell cycle progression at the G1-S phase transition and the authors have suggested that this dysregulation...
results in the enhancement of apoptosis.

The underlying mechanism as to how HpGGT triggers apoptosis was not addressed in these earlier studies. Interestingly, we had recently reported that exposure of gastric cells to purified native HpGGT resulted in the formation of reactive oxygen species (ROS), in particularly H2O2, which is a known inducer of apoptosis. Accordingly, we and others have shown that pro-oxidant products generated by HpGGT through glutathione degradation triggered apoptosis in gastric epithelial cells, hence providing the link between HpGGT and its ability to induce apoptotic cell death. This model also corroborates with earlier observations whereby H. pylori infection was found to be associated with excessive ROS levels and diminished glutathione levels in the infected gastric mucosa.

Interestingly, apart from gastric cells, HpGGT has also recently been shown to be capable of inducing mitochondria-mediated apoptosis in a human cholangiocarcinoma cell line. This suggests that HpGGT-induced apoptosis is not only restricted to gastric epithelial cells and may possibly occur via a common pathway across different cell types. Hence, future studies investigating the effects of HpGGT on other cell lines may be of particular interest.

HpGGT is pro-inflammatory

H. pylori-infected subjects develop an inflammatory and immune response towards the pathogen characterized by infiltration of the mucosa by polymorphonuclear and mononuclear leukocytes as well as neutrophils. However, this response is ineffective in clearing the bacteria, thereby resulting in chronic gastric inflammation. With regard to the role of HpGGT in inflammation, Busiello et al. showed by using the MKN28 gastric cell line that HpGGT upregulates cyclooxygenase-2 (COX-2) expression and its enzymatic product prostaglandin E2, whose role in inflammation has been well established. Notably, COX-2 has been found to be overexpressed in various types of cancer including gastric carcinoma and has roles in promoting cell proliferation, angiogenesis and metastasis.

In addition, our group had also previously reported that purified native HpGGT stimulated the activation of the transcription factor NF-κB, leading to increased expression and secretion of the pro-inflammatory chemokine interleukin-8 (IL-8) from both AGS and primary gastric epithelial cells. HpGGT-induced IL-8 production in gastric cells may thus contribute to the recruitment of immune cells to the sites of infection and the maintenance of chronic inflammation in the gastric mucosa. Importantly, H. pylori infection has been associated with elevated levels of gastric IL-8, a potent neutrophil recruitment factor thought to play a pivotal role in the immunopathogenesis of H. pylori infections. Collectively, these results strongly support the contributory role of HpGGT in pro-inflammatory processes.

Increase in epidermal growth factor-related peptide expression

HpGGT upregulates the expression of heparin-binding epidermal growth factor-like growth factor (HB-EGF), a member of the EGF-like growth factor family of proteins and a ligand of epidermal growth factor receptor (EGFR). HB-EGF is first synthesized as a membrane-anchored precursor which is subsequently cleaved at the cell surface, yielding the mature, soluble form. Binding of soluble HB-EGF to EGFR activates the Raf/Ras/MEK/Erk and phosphoinositide-3-kinase (PI3K)/Akt pathways which promote cell survival and proliferation. Importantly, expression of HB-EGF has been reported to be increased in various cancer types including hepatic, breast, ovarian and gastric cancer. Furthermore, both expression and protein shedding of HB-EGF have been found to be increased in H. pylori infections and this has been suggested to contribute to gastric cancer progression by promoting epithelial-mesenchymal transition. Till date, the definitive role of HpGGT-induced HB-EGF expression in gastric cells has not been clearly elucidated but its potential role in carcinogenesis would certainly be an area worth investigating in future studies.

Disturbing the balance between cell survival and cell death: Link to carcinogenesis?

It seems contradictory for HpGGT to have both apoptosis- and survival-promoting properties. However, both effects may play different roles during the various events of carcinogenesis. HpGGT-induced apoptosis has been suggested to be important particularly in the early events of carcinogenesis. This is because an increase in the rate of apoptosis in a subpopulation of cells could induce a secondary hyperproliferative response where the gastric mucosa attempts to maintain its cell mass. Hyperproliferation, coupled with DNA damage induced by HpGGT, could then potentially lead to an increase in the mutation rates of important tumor suppressor genes in these cells, resulting in their transformation to a malignant phenotype. In tumor cells that have become apoptosis-resistant, it is then possible that HpGGT-induced COX-2 upregulation in these cells contribute to their continuous survival and proliferation. This postulation is partially supported by the finding that HpGGT-dependent induction of COX-2 mRNA is higher in MKN28 cells compared to AGS cells as observed by Busiello et al. Although AGS and MKN28 cells are both carcinoma cells lines, MKN28 cells have a mutation in p53, an important tumor suppressor involved in the control of cell cycle progression and apoptosis. Thus, it is plausible that COX-2-induced cell proliferation affects apoptosis-resistant tumor cells to a greater extent, leading to the survival and proliferation of these cancerous cells.
H. pylori γ-glutamyl transpeptidase (HpGGT) is emerging as a formidable virulence factor in modulating the immune response and influencing the persistence of H. pylori in the gastric mucosa. Apart from directly influencing gastric epithelial cells, an increasing body of evidence is pointing to the role of HpGGT in modulating the immune response. Being a secreted bacterial protein, the possibility of HpGGT interacting with other non-gastric cells is highly possible, especially since H. pylori is capable of disrupting gastric epithelial barrier function. Interestingly, the effects of HpGGT on immune cells have been investigated in various studies and have yielded important results and implications.

**Effects on T cells**
In one of the earlier studies investigating the effects of HpGGT on immune effector cells, Schmees et al found that HpGGT was capable of abrogating the proliferation of both primary and immortalized human T cells. A corresponding cell cycle arrest at the G1 phase was observed in these cells, which possibly occurred due to disruption of a Ras-dependent signalling pathway. Intriguingly, inhibition of T cell proliferation by HpGGT was found in the same study to be mediated by an apoptosis-independent mechanism which is different from that observed in gastric epithelial cells, suggesting that separate mechanisms exist in both cell types. HpGGT-induced inhibition of T cell proliferation has been proposed to have immunosuppressive effects which contribute to the persistence of H. pylori infections. Interestingly, in a separate study by Beigier-Bompadre et al, HpGGT-dependent antiproliferative effect on T cells was found to be modulated by bacterial cholesterol/cholesterol α-glucoside content, suggesting that HpGGT works with other H. pylori factors to shape the immune response during an infection.

Working together with H. pylori lipopolysaccharide and vacuolating cytotoxin (VacA), HpGGT was recently reported to upregulate microRNA-155 (miR-155) expression in CCRF-CEM cells, the first study to investigate the regulation of miRNAs by H. pylori in T cells. Clinically, miR-155 has been shown to be induced upon H. pylori infection and has also been associated with the development of diffuse large B-cell lymphoma. In addition, HpGGT-induced miR-155 expression in both CCRF-CEM cells and primary human peripheral blood mononuclear cells was found to be dependent on forkhead box P3 (Foxp3) and requires activation of the cyclic adenosine monophosphate cascade. Foxp3 is a transcriptional factor which is different from that observed in gastric epithelial cells, suggesting that separate mechanisms exist in both cell types.
HpGGT is associated with PUD as strains isolated from PUD patients had significantly higher HpGGT activity compared to those from NUD patients (P < 0.001).

HpGGT is a leading factor in H. pylori-mediated apoptosis induction.

HpGGT induces apoptosis via a mitochondria-mediated pathway.

HpGGT induces cell cycle arrest at the G1-S phase transition. (The authors propose this dysregulation enhances apoptosis induction)

HpGGT-mediated oxidative stress is required for HpGGT-associated apoptosis.

HpGGT is able to upregulate COX-2 expression and its enzymatic product, prostaglandin E2.

Purified native HpGGT activates NF-κB and upregulates IL-8 production in gastric epithelial cells.

HpGGT upregulates HB-EGF expression via activation of a phosphatidylinositol-3 kinase and p38 kinase-dependent signalling transduction pathway. Increase in HB-EGF promotes cell survival and proliferation.

HpGGT inhibits T cell proliferation by inducing cell cycle arrest in the G1 phase, possibly through the disruption of a Ras-dependent signalling pathway.

HpGGT antiproliferative activity on T cells is modulated by the bacterial cholesterol/cholesterol α-glucoside content.

HpGGT works with H. pylori VacA and lipopolysaccharide to upregulate miRNA-155 expression in CCRF-CEM cells. This was dependent on Foxp3 transcription factor and requires activation of the cAMP cascade.

Both HpGGT and VacA independently interfere with dendritic cell maturation, possibly contributing to dendritic cell tolerization and hence promoting the persistence of H. pylori infection.


cAMP: Cyclic adenosine monophosphate; COX-2: Cyclooxygenase-2; EGFR: Epidermal growth factor receptor; Foxp3: Forkhead box P3; H. pylori: Helicobacter pylori; HB-EGF: Heparin-binding epidermal growth factor-like growth factor; IL-8: Interleukin-8; miRNA: microRNA; NAC: N-acetylcysteine; NF-κB: Nuclear factor-kappa B; NUD: Non-ulcer dyspepsia; PUD: Peptic ulcer disease; VacA: Vacuolating cytotoxin.

**HpGGT affects dendritic cells**

The ability of H. pylori to reprogram dendritic cells (DCs) towards a tolerogenic phenotype has been implicated in the development of immune tolerance and favors persistence of the bacteria in the gastric mucosa [69]. Recently, it has been reported that both VacA and HpGGT play critical roles in DC reprogramming by interfering with their maturation and that this occurred in a manner independent of their suppressive effects on T cells [69]. The underlying mechanisms dictating how both factors prevent DC maturation and promote tolerization were not clearly elucidated in the study but it is known that they act via non-redundant pathways since neither of the respective isogenic mutants was capable of rescuing the effect of the other.
CONCLUSION

*H. pylori* produces a potent virulence factor, HpGGT, which causes injury to host cells through multiple ways (illustrated in Figure 1 and summarized in Table 1), many of which have been implicated in carcinogenesis. To gastric epithelial cells, it induces mitochondrial-dependent apoptosis, cell cycle arrest and production of the pro-inflammatory IL-8. To T cells, it inhibits their proliferation and upregulates miR-155 expression while to DCs, it skews them towards a tolerogenic phenotype. Taken together, it is clear that HpGGT plays an important role in the pathogenesis of *H. pylori* by directly damaging gastric epithelial cells and also in modulating the immune response towards the bacterium, resulting in persistent colonization by the organism. Despite the relatively numerous reports on its effects on the host, much of the underlying mechanisms of how such effects are brought about by HpGGT remain ill-defined. Future studies on the molecular mechanisms responsible for the actions of HpGGT will be required to better understand the role of HpGGT in the pathogenesis of *H. pylori*. This will be particularly important in the consideration of HpGGT as a viable anti-*H. pylori* target. In addition, it could also be worthwhile to evaluate the efficacy of HpGGT as a potential vaccine candidate against *H. pylori* infections especially since the protein is present in all *H. pylori* strains.

REFERENCES

1. Covacci A, Telford LL, Del Giudice G, Parsonnet J, Rappuoli R. Helicobacter pylori virulence and genetic geography. *Science* 1999; 284: 1328-1333 [PMID: 10334982 DOI: 10.1126/science.284.5418.1328]

2. Linz B, Balloux F, Moodley Y, Manica A, Liu H, Roumagnac P, Falush D, Stammer C, Prugnolle F, van der Merwe SW, Yamaoka Y, Graham DV, Perez-Trallero E, Wadstrom T, Suerbaum S, Achtman M. An African origin for the intimate association between humans and Helicobacter pylori. *Nature* 2007; 445: 915-918 [PMID: 17287725 DOI: 10.1038/nature05652]

3. Cover TL, Blaser MJ. Helicobacter pylori gastroduodenal disease. *Annu Rev Med* 1992; 43: 135-145 [PMID: 1580578 DOI: 10.1146/annurev.me.43.020192.001301]

4. Peterson WL. Helicobacter pylori and peptic ulcer disease. *N Engl J Med* 1991; 324: 1043-1048 [PMID: 2005942 DOI: 10.1056/NEJM199110313241507]

5. Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, Orentreich N, Vogelman JH, Friedman GD. Helicobacter pylori infection and gastric lymphoma. *Am J Gastroenterol* 1994; 89: 1564-1573 [PMID: 10074267 DOI: 10.1111/j.1572-0241.1994.tb02591.x]

6. De Koster E, Buset M, Fernandez E, Deltenre M. Helicobacter pylori: the link with gastric cancer. *Eur J Cancer Prev* 1994; 3: 247-257 [PMID: 9078049 DOI: 10.1111/j.1360-1378.1994.tb00030.x]

7. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. *Lancet* 1983; 1: 1273-1275 [PMID: 8134606 DOI: 10.1016/s0140-6736(83)92719-8]

8. Covacci A, Censi S, Bugnoli M, Petracca R, Burroni D, Macchia G, Massone A, Papini E, Xiang Z, Figura N. Molecular characterization of the 129-kDa immunodominant antigen of Helicobacter pylori isolated with cytotoxicity and duodenal ulcer. *Proc Natl Acad Sci USA* 1993; 90: 5791-5795 [PMID: 8516329 DOI: 10.1073/pnas.90.12.5791]

9. Cover TL, Blaser MJ. Purification and characterization of the vacuolating toxin from Helicobacter pylori. *J Biol Chem* 1992; 267: 10570-10575 [PMID: 1587837]

10. Atherton JC, Peek RM, Tham KT, Cover TL, Blaser MJ. Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori. *Gastroenterology* 1997; 112: 92-99 [PMID: 8978347 DOI: 10.1016/s0016-5085(97)02233-3]

11. van Doorn LJ, Figueiredo C, Sanna R, Plaisier A, Schneeberger P, de Boer W, Quint W. Clinical relevance of the cagA, vacA, and iceA status of Helicobacter pylori. *Gastroenterology* 1998; 115: 58-66 [PMID: 9649459 DOI: 10.1016/S0016-5085(98)70365-4]

12. Yamaoka Y, Kodama T, Gutierrez O, Kim JG, Kashima K, Graham DY. Relationship between Helicobacter pylori iceA, cagA, and vacA status and clinical outcome: studies in four different countries. *J Clin Microbiol* 1999; 37: 2274-2279 [PMID: 10364997]

13. Zheng PY, Hua J, Yeoh KG, Ho B. Association of peptic ulcer with increased expression of Lewis antigens but not cagA, iceA, and vacA in Helicobacter pylori isolates in an Asian population. *Gut* 2000; 47: 18-22 [PMID: 10861298 DOI: 10.1136/gut.47.1.18]

14. Boanca G, Sand A, Barycki JJ. Uncoupling the enzymatic and autophagy processing activities of Helicobacter pylori gamma-glutamyltranspeptidase. *J Biol Chem* 2006; 281: 19029-19037 [PMID: 16672227 DOI: 10.1074/jbc.M603381200]

15. Chevalier C, Thibeuge JM, Ferrero RL, Labigne A. Essential role of Helicobacter pylori gamma-glutamyltranspeptidase for the colonization of the gastric mucosa of mice. *Mol Microbiol* 1999; 31: 1359-1372 [PMID: 10209957 DOI: 10.1046/j.1365-2958.1999.01271.x]

16. Gong M, Ling SS, Lui SY, Yeoh KG, Ho B. Helicobacter pylori gamma-glutamyl transpeptidase is a pathogenic factor in the development of peptic ulcer disease. *Gastroenterology* 2010; 139: 564-573 [PMID: 20347814 DOI: 10.1013/j.gastro.2010.03.050]

17. Gong M, Ho B. Prominent role of gamma-glutamyl-transpeptidase on the growth of Helicobacter pylori. *World J Gastroenterol* 2004; 10: 2994-2996 [PMID: 15378780]

18. Shibayama K, Wachiyo J, Arakawa Y, Saidijam M, Rutherdorff NG, Henderson PJ. Metabolism of glutamine and glutathione via gamma-glutamyltranspeptidase and glutamate transport in Helicobacter pylori: possible significance in the pathophysiology of the organism. *Mol Microbiol* 2007; 64: 396-406 [PMID: 17381553 DOI: 10.1111/j.1365-2958.2007.05661.x]

19. McGovern KJ, Blanchard TG, Gutierrez JA, Czinn SJ, Krakowska S, Youngman P. Gamma-Glutamyltransferase is a Helicobacter pylori virulence factor but is not essential for colonization. * Infect Immun* 2001; 69: 4168-4173 [PMID: 11349094 DOI: 10.1128/IAI.69.6.4168-4173.2001]

20. Moss SF, Calam J, Agarwal B, Wang S, Holt PR. Induction of gastric epithelial apoptosis by Helicobacter pylori. *Gut* 1996; 38: 498-501 [PMID: 8707076 DOI: 10.1136/gut.38.4.498]

21. Wagner S, Beil W, Westermann J, Logan RP, Bock CT, Trautwein C, Bleck JS, Manns MP. Regulation of gastric epithelial cell growth by Helicobacter pylori: evidence for a major role of apoptosis. *Gastroenterology* 1997; 113: 1836-1847 [PMID: 9394723 DOI: 10.1016/s0016-5085(97)00039-9]

22. Konturek PC, Pierzchalski P, Konturek SJ, Meixner H, Faller G, Kirchner T, Hahn EG. Helicobacter pylori induces apoptosis in gastric mucosa through an upregulation of Bax expression in humans. *Scand J Gastroenterol* 1999; 34: 375-383 [PMID: 10365897 DOI: 10.1080/0036552970026380]

23. Shibayama K, Kamachi K, Nagata N, Yagi T, Nada T, Doi Y, Shibata N, Yamaoka K, Yamane K, Kato H, Iinuma Y, Arakawa Y. A novel apoptosis-inducing protein from Helicobacter pylori. *Mol Microbiol* 2003; 47: 443-451 [PMID: 12519194 DOI: 10.1046/j.1365-2958.2003.03035.x]

Ling SSM et al. HpGGT: A formidable virulence factor
Kim KM, Lee SG, Park MG, Song JY, Kang HL, Lee WK, Cho MJ, Rhee KH, Youn HS, Baik SC. Gamma-glutamyltranspeptidase of Helicobacter pylori induces mitochon-
drained apoposis in AGS cells. *Biochem Biophys Res Commun* 2007; 358: 562-567 [PMID: 17307146 DOI: 10.1016/j.bbr.2007.02.021]

Kim KM, Lee SG, Kim JM, Kim DS, Song JY, Kang HL, Lee WK, Cho MJ, Rhee KH, Youn HS, Baik SC. Helicobacter pylori gamma-glutamyltranspeptidase induces cell cycle arrest at the GI-S phase transition. *J Microbiol* 2010; 48: 372-377 [PMID: 20571956 DOI: 10.1007/s12277-010-9293-8]

Li J, Huang CV, Zheng RL, Cai KR, Li JF. Hydrogen perox-
ide induces apoptosis in human hepatic cells and alters cell redox status. *Cell Biol Int* 2000; 24: 9-23 [PMID: 10826769 DOI: 10.1006/cbir.1999.0438]

Mao Y, Song C, Gai Q, Liu M, Luo H, Shi M, Ouyang G, Bao S. Hydrogen peroxide-induced apoptosis in human gas-
tric carcinoma MGC803 cells. *Cell Biol Int* 2006; 30: 332-337 [PMID: 16536611 DOI: 10.1016/j.cellbi.2005.12.008]

Singh M, Sharma H, Singh N. Hydrogen peroxide induces apoposis in Hela cells through mitochondrial pathway. *Mitochondrion* 2007; 7: 367-373 [PMID: 17855174 DOI: 10.1016/j.mito.2007.07.003]

Flahou B, Haebebrack F, Chiers K, Van Deun K, De Smet L, Devreee B, Vandenberge I, Favoreel H, Smet A, Pasmans F, D’Herde K, Ducatelle R. Gastric epithelial cell death caused by Helicobacter suis and Helicobacter pylori γ-glutamyl transpeptidase is mainly glutathione depletion-depen-
dent. *Cell Microbiol* 2011; 13: 1933-1955 [PMID: 21899697 DOI: 10.1111/j.1462-5822.2011.01682.x]  

Davies GR, Simmonds NJ, Stevens TR, Sheaff MT, Banat-
vala N, Laurenson IF, Blake DR, Rampton DS. Helicobacter pylori stimulates antral mucosal reactive oxygen metabolite production in vivo. *Gut* 1994; 35: 179-185 [PMID: 8307467 DOI: 10.1136/gut.35.2.179]

Ding SZ, Minohara Y, Fan XJ, Wang J, Reyes VE, Patel J, Dirden-Kramer B, Boldogh I, Ernst PB, Crowe SE. Helico-
bacter pylori infection induces oxidative stress and pro-
celled programmed cell death in human gastric epithelial cells. *Infect Immun* 2007; 75: 4030-4039 [PMID: 17562277 DOI: 10.1128/IAL00172-07]

Shirin H, Pinto JT, Liu LU, Merzianu M, Sordillo EM, Moss SF. Helicobacter pylori decreases gastric mucosal glutathi-
one. *Cancer Lett* 2001; 164: 127-133 [PMID: 11798260 DOI: 10.1016/S0304-3835(01)00383-3]

Boonyanugomol W, Chomvarin C, Song JY, Kim KM, Kim JM, Cho MJ, Lee WK, Kang HL, Rhee KH, Sripa B, Hahnvajanawong C, Baik SC. Effects of Helicobacter pylori γ-glutamyltranspeptidase on apoptosis and inflammation in human biliary cells. *Dig Dis Sci* 2012; 57: 2615-2624 [PMID: 22581342 DOI: 10.1007/s10292-012-2216-2]

Dundon WG, Nishioka H, Poleni G, Papinutto E, Zanotti N, Ishikawa M, Mekada E, Taniguchi N. Phorbol ester in-
volves in triple-negative and trastuzumab-resistant breast cancer. *Clin Cancer Res* 2011; 17: 3988-3998 [PMID: 21837009 DOI: 10.1158/1078-0432.CCR-10-2845]

Koter BS, Schatzl HM, Matuszewski S, Juchelka A, Onken H, Redlich K, Steiner H, Stein A, Seitz H, Koller K, Hohenberger P. Expression of cyclooxygenase-2 gene in esophageal carcinoma. *Gastroenterology* 2004; 127: 2379-2387 [PMID: 15544750 DOI: 10.1053/j.gastro.2004.09.015]

Ling SSM et al. HpGGT: A formidable virulence factor

**References**
Ling SSM et al. HpGGT: A formidable virulence factor

Clin Cancer Res 2005; 11: 4783-4792 [PMID: 16000575 DOI: 10.1186/1078-0432.ccr-04-1426]

53 Murayama Y, Miyagawa J, Shinomura Y, Kanayama S, Isozaki K, Yamamori K, Mizuno H, Ishiguro S, Kiyohara T, Miyazaki Y, Tamiguchi N, Higashiyama S, Matsuzawa Y. Significance of the association between heparin-binding epidermal growth factor-like growth factor and CD9 in human gastric cancer. Int J Cancer 2002; 98: 505-513 [PMID: 11920609 DOI: 10.1002/ijc.10198]

54 Dickson JH, Grabowska A, El-Zaataari M, Atherton J, Watson SA. Helicobacter pylori can induce heparin-binding epidermal growth factor expression via gastrin and its receptor. Cancer Res 2006; 66: 7524-7531 [PMID: 16885530 DOI: 10.1158/0008-5472.can-05-3246]

55 Yin Y, Grabowska AM, Clarke PA, Whelband E, Robinson K, Argent RH, Tobias A, Kumari R, Atherton JC, Watson SA. Helicobacter pylori potentiates epithelial: mesenchymal transition in gastric cancer: links to soluble HB-EGF, gastrin and matrix metalloproteinase-7. Gut 2010; 59: 1037-1045 [PMID: 20584780 DOI: 10.1136/gut.2009.199794]

56 Shirin H, Moss SF. Helicobacter pylori induced apoptosis. Gut 1998; 43: 592-594 [PMID: 9824331 DOI: 10.1136/gut.43.5.592]

57 Matozaki T, Sakamoto C, Matsuda K, Suzuki T, Konda Y, Nakano O, Wada K, Uchida T, Nishisaki H, Nagao M. Missense mutations and a deletion of the p53 gene in human gastric cancer. Biochem Biophys Res Commun 1992; 182: 215-223 [PMID: 1370612 DOI: 10.1016/S0006-291X(05)80133-0]

58 Bumann D, Aksu S, Wendland M, Janek K, Zinny-Arndt U, Sabarth N, Meyer TF, Jungblut PR. Proteome analysis of secreted proteins of the gastric pathogen Helicobacter pylori. Infect Immun 2002; 70: 3396-3403 [PMID: 12065478 DOI: 10.1128/IAI.70.7.3396-3403.2002]

59 Wroblewski LE, Shen L, Ogden S, Romero-Gallo J, Lapierre LA, Israel DA, Turner JR, Peek RM. Helicobacter pylori dysregulation of gastric epithelial tight junctions by urease-mediated myosin II activation. Gastroenterology 2009; 136: 236-246 [PMID: 18996125 DOI: 10.1053/j.gastro.2008.10.011]

60 Schnees C, Prinz C, Trettau T, Rad R, Hengst L, Voland P, Bauer S, Brenner L, Schmid RM, Gerhard M. Inhibition of T-cell proliferation by Helicobacter pylori gamma-glutamyl transpeptidase. Gastroenterology 2007; 132: 1820-1833 [PMID: 17484877 DOI: 10.1053/j.gastro.2007.02.031]

61 Beigier-Bompadre M, Moos V, Belogolova E, Allers K, Schneider T, Churin Y, Ignatius R, Meyer TF, Aebscher T. Modulation of the CD4+ T-cell response by Helicobacter pylori depends on known virulence factors and bacterial cholesterol and cholesterol α-glucoside content. J Infect Dis 2011; 204: 1339-1348 [PMID: 21921201 DOI: 10.1093/infdis/jir547]

62 Fassi Fehri L, Koch M, Belogolova E, Khalil H, Bolz C, Kalali B, Mollenkopf HJ, Beigier-Bompadre M, Karlas A, Schneider T, Churin Y, Gerhard M, Meyer TF. Helicobacter pylori induces miR-155 in T cells in a CAMP-Foxp3-dependent manner. PLoS One 2010; 5: e9500 [PMID: 20209161 DOI: 10.1371/journal.pone.0009500]

63 Xiao B, Liu Z, Li BS, Tang B, Li W, Guo G, Shi Y, Wang F, Wu Y, Tong WD, Guo Y, Mao HX, Zou QM. Induction of microRNA-155 during Helicobacter pylori infection and its negative regulatory role in the inflammatory response. J Infect Dis 2009; 200: 916-925 [PMID: 19650740 DOI: 10.1086/605443]

64 Kluiver J, Poppema S, de Jong D, Blokzijl T, Harms G, Jacobs S, Kroesen BJ, van den Berg A. BIC and mir-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol 2005; 207: 243-249 [PMID: 16041695 DOI: 10.1002/path.1825]

65 Rai D, Karanti S, Jung I, Dahia PL, Aguilar RC. Coordinated expression of microRNA-155 and predicted target genes in diffuse large B-cell lymphoma. Cancer Genet Cytogenet 2008; 181: 8-15 [PMID: 18262046 DOI: 10.1016/j.cancergen.2007.10.008]

66 Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs T-cell proliferation by Helicobacter pylori gamma-glutamyl transpeptidase and vacuolating cytotoxin promote gastric persistence and immune tolerance. Proc Natl Acad Sci USA 2013; 110: 3047-3052 [PMID: 23382221 DOI: 10.1073/pnas.1211248110]

67 Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22: 531-562 [PMID: 15032886 DOI: 10.1146/annurev.immunol.21.120601.141122]

68 Oertli M, Noben M, Engler DB, Semper RP, Reuter S, Maxeiner J, Gerhard M, Taube C, Müller A. Helicobacter pylori γ-glutamyl transpeptidase and vacuolating cytotoxin promote gastric persistence and immune tolerance. Proc Natl Acad Sci USA 2013; 110: 3047-3052 [PMID: 23382221 DOI: 10.1073/pnas.1211248110]

69 Zhang M, Liu M, Luther J, Kao YJ. Helicobacter pylori directs tolerogenic programming of dendritic cells. Gut Microbes 2010; 1: 325-329 [PMID: 21327041 DOI: 10.4161/gmic.1.5.13052]
